Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the Safety and Effectiveness of the UV-X System for Corneal Collagen
Cross-Linking in Eyes with Corneal Infection. The treatment of UV-X system is to use the
eyedrops of the riboflavin, also known as vitamin B2, and ultraviolet A (UVA) light. The eye
drops are placed in affected eye and then affected cornea is exposed to UVA.
UVA/riboflavin corneal collagen cross-linking was first used to treat patients in 1998 in
Dresden, Germany. Data to date obtained mostly by physicians outside the United States has
strongly suggested this treatment as an acceptable alternative, and many subjects have had a
lasting effect (no progression) 3-5 years after their initial treatment.